Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis

Journal of Autoimmunity

Volumn 10, Issue 1, 1997, Pages 87-97

  Van Der Lubbe, P A ^a   Breedveld, F C ^a   Tak, P P ^a   Schantz, A ^b   Woody, J ^b   Miltenburg, A M M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Rheumatology C4 R ^*

Author keywords

CD4 monoclonal antibodies; human anti monoclonal antibodies; lymphokine production; rheumatoid arthritis; T cells

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; CHIMERIC ANTIBODY; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 4; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

EID: 0031081473     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1996.0113     Document Type: Article

References (40)

1. Panayi G.S., Lanchbury J.S., Kingsley G.H. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis (editorial). Arthritis Rheum. 35:1992;729-735.
2. Janeway C.A., Haque S., Smith L.A., Saizawa K. The role of the murine L3T4 molecule in T cell activation: differential effects of anti-L3T4 on activation by monoclonal anti-receptor antibodies. J. Mol. Cell. Immunol. 3:1987;121-131.
3. Dalesandro M.R., Pak K.Y., Tam S., Wilson E., Looney J.E., Knight M.D., Ghrayeb J., Rieber E.P., Riethmüller G., Daddona P. Effects of isotype and Fc region on in vitro function of a mouse/human chimeric CD4 antibody. Int. Immunol. 5:1993;283-291.
4. 1. J. Immunol. 138:1987;3247-3253.
5. Cobbold S.P., Qin S., Leong L.Y.W., Martin G., Waldmann H. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol. Rev. 129:1992;165-201.
6. Ranges G.E., Sriram S., Cooper S.M. Prevention of Type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J. Exp. Med. 162:1985;1105-1110.
7. Sablinski T., Hancock W.W., Tilney N.L., Kupiec-Weglinski J.W. CD4 monoclonal antibodies in organ transplantation: a review of progress. Transplantation. 52:1991;579-589.
8. Riethmüller G., Rieber E.P., Kiefersauer S., Prinz J., van der Lubbe P.A., Meiser B., Breedveld F.C., Eisenburg J., Krüger K., Deusch K., Sanders M., Reiter C. From antilymphocyte serum to therapeutic monoclonal antibodies: first experiences with a chimeric CD4 antibody in the treatment of autoimmune disease. Immunol. Rev. 129:1992;81-104.
9. Herzog C, Walker C., Müller W., Rieber P., Reiter C., Riethmüller G., Wassmer P., Stockinger H., Madic O., Pichler W.J. Anti-CD4 antibody treatment of patients with rheumatoid arthritis. I. Effect on clinical course and circulating T cells. J. Autoimmun. 2:1989;627-642.
10. Horneff G., Burmester G.R., Emmrich F., Kalden J.R. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum. 34:1991;129-140.
11. Goldberg D., Morel P., Chatenoud L., Boitard C., Menkes C.J., Bertoye P.H., Revillard J.P., Bach J.F. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J. Autoimmun. 4:1991;617-630.
12. Moreland L.W., Bucy R.P., Tilden A., Pratt P.W., LoBuglio A.F., Khazaeli M., Everson M.P., Daddona P., Ghrayeb J., Kilgarriff C., Sanders M.E., Koopman W.J. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum. 36:1993;307-318.
13. Van der Lubbe P.A., Reiter C., Breedveld F.C., Krüger K., Schatten-kirchner M., Sanders M.E., Riethmüller G. Chimeric CD4 monoclonal antiobody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 36:1993;1375-1379.
14. Van der Lubbe P.A., Dijkmans B.A.C., Markusse H.M., Nässander U., Breedveld F.C. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum. 38:1995;1097-1106.
15. Moreland L., Pratt P., Mayes M., Postlethwaite A., Weisman M., Schnitzer T., Lightfoot R., Calabrese L., Koopman W. Minimal efficacy of a depleting chimeric anti-CD4 (cM-T412) in treatment of patients with refractory rheumatoid arthritis receiving concomitant methotrexate (abstract). Arthritis Rheum. 36 (suppl 9):1993.
16. Choy E.H.S., Chikanza I.C., Kingsley G.H., Corrigall V., Panayi G.S. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand. J. Immunol. 36:1992;291-298.
17. Wendling D., Racadot E., Morel-Fourrier B., Wijdenes J. Treatment of rheumatoid arthritis with anti-CD4 monoclonal antibody: open study of 25 patients with the B-F5 clone. Clin. Rheumatol. 11:1992;542-547.
18. Van der Lubbe P.A., Reiter C., Miltenburg A.M., Krüger K., De Ruyter A.N., Rieber E.P., Bijl J.A., Riethmüller G., Breedveld F.C. Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal antibody (cM-T412): immunopharmacological aspects and mechanisms of action. Scand. J. Immunol. 39:1994;286-294.
19. Weyand C.M., Goronzy J., Swartztrauber K., Fathman C.G. Immunosuppression by anti-CD4 treatment in vivo. Cellular and humoral responses to alloantigens. Transplantation. 47:1989;1039-1042.
20. Ranges G.E., Cooper S.M., Sriram S. In vivo immunomodulation by monoclonal anti-L3T4. 1. Effects on humoral and cell-mediated immune response. Cell. Immunol. 106:1987;163-173.
21. Benjamin R.J., Waldman H. Induction of tolerance by monoclonal antibody therapy. Nature. 320:1986;449-451.
22. Gutstein N.L., Seaman W.E., Scott J.H., Wofsy D. Induction of tolerance by administration of monoclonal antibody to L3T4. J. Immunol. 137:1986;1127-1133.
23. Jamali I., Field E.H., Fleming A., Cowdery J.S. Kinetics of anti-CD4-induced T helper cell depletion and inhibition of function: activation by the CD3 pathway inhibits anti-CD4-mediated T cell elimination and down-regulation of cell surface CD4. J. Immunol. 148:1992;1613-1619.
24. Chase J.H., Cowdery J.S., Field E.H. Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting naive CD4 cells and spares activated CD4 cells. J. Immunol. 152:1994;405-412.
25. Field E.H., Rouse T.M., Fleming A.L., Jamali I., Cowdery J. Altered IFN-γ and IL-4 pattern lymphokine secretion in mice partially depleted of CD4 T cells by anti-CD4 monoclonal antibody. J. Immunol. 149:1992;1131-1137.
26. Van der Meide P.H., Dubbeld M., Schellekens H. Monoclonal antibodies to human immune interferon and their use in a sensitive solid-phase ELISA. J. Imm. Methods. 79:1985;293-305.
27. Kloppenburg M., Miltenburg A.M.M., Daha M.R., Dijkmans B.A.C., Verweij C.L., Breedveld F.C. Minocycline inhibits T lymphocyte functions in vitro. What is the effect in vivo? The tetracycline derivate minocycline as treatment for rheumatoid arthritis. 1996;Leiden University Press.
28. Choy E.H.S., Pitzalis C., Bijl J.A., Kingsley G.H., Panayi G.S. The importance of dose and dosing regimen of anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis (abstract). Arthritis Rheum. 36 (suppl 9):1993.
29. Hom J.T., Butler L.D., Riedl P.E., Bendele A.M. The progression of inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities. Eur. J. Immunol. 18:1988;881-888.
30. Van den Broek M.F., van de Langerijt L.G.M., van Bruggen M.C.J., Billingham M.E.J., van den Berg W.B. Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis. Eur. J. Immunol. 22:1992;57-61.
31. Billingham M.E.J., Hicks C., Carney S. Monoclonal antibodies and arthritis. Agents and Actions. Eur. J. Immunol. 29:1990;77-87.
32. Williams R.O., Mason L.J., Feldmann M., Maini R.N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA. 91:1994;2762-2766.
33. +. Eur. J. Immunol. 18:1988;811-816.
34. Titus R.G., Ceredig R., Cerottini J.C., Louis J.A. Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice. J. Immunol. 135:1985.
35. Newell M.K., Haughn L.J., Maroun C.R., Julius M.H. Death of mature T cells by separate ligation of CD4 and the T-cell receptor for antigen. Nature. 347:1990;286-289.
36. Facchinetti A., Panozzo M., Pertile P., Tessarollo L., Biasi G. In vivo and in vitro death of mature T cells induced by separate signals to CD4 and alpha beta TCR. Immunobiology. 185:1992;380-389.
37. Goldschmidt T.J., Andersson M., Malmstrom V., Holmdahl R. Activated type II collagen reactive T cells are not eliminated by in vivo anti-CD4 treatment: implications for therapeutic approaches on autoimmune arthritis. Immunobiology. 184:1992;359-371.
38. Akbar A.N., Borthwick N., Salmon M., Gombert W., Bofill M., Shamsadeen N., Pilling D., Pett S., Grundy J.E., Janossy G. The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J. Exp. Med. 178:1993;427-438.
39. Isaacs J.D. The antiglobulin response to therapeutic antibodies. Sem. Immunol. 2:1990;449-456.
40. Deckert P.M., Ballmaier M., Lang S., Deicher H., Schedel I. CD4-imitating human antibodies in HIV infection and anti-idiotypic vaccination. J. Immunol. 156:1996;826-833.